

10/519580

EXPRESS MAIL LABEL NO. EV352377100US
Date of Deposit: December 27, 2004

Dkt Rec'd POW/PT 27 DEC 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-66176-05
	Application Number	Not yet assigned
	Filed	Herewith
	First Named Inventor	Kashmiri
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
/PKT/		4,816,567	28 March 1989	Cabilly <i>et al.</i>
		5,472,693	5 Dec 1995	Gourlie <i>et al.</i>
		5,482,040	9 Jan 1996	Martin, Jr.
		5,512,443	30 April 1996	Schlom <i>et al.</i>
		5,534,254	9 July 1996	Huston <i>et al.</i>
		5,585,089	17 Dec 1996	Queen <i>et al.</i>
		5,688,657	18 Nov 1997	Tsang <i>et al.</i>
		5,976,531	2 Nov 1999	Mezes <i>et al.</i>
		5,976,845	2 Nov 1999	Mezes <i>et al.</i>
		5,994,511	30 Nov 1999	Lowman <i>et al.</i>
		6,054,297	25 April 2000	Carter <i>et al.</i>
		6,180,370	30 Jan 2001	Queen <i>et al.</i>
		6,495,137	17 Dec 2002	Mezes <i>et al.</i>

EXAMINER SIGNATURE: /Parithosh K Tungaturthi/	DATE CONSIDERED: 12/20/2007
--------------------------------------------------	--------------------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/15/95 Q.C.

EXPRESS MAIL LABEL NO. EV352377100US

Date of Deposit: December 27, 2004

27 DEC 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66176-05
		Application Number	Not yet assigned
		Filed	Herewith
		First Named Inventor	Kashmiri
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
/PKT/		Canada	2,068,593	8 July 2003	Daugherty <i>et al.</i>
		Canada	2,131,355	17 April 2001	Kashmiri <i>et al.</i>
		EPC	EP0239400	30 Sep 1987	Winter
		EPC	EP0365997	2 May 1990	Gourlie <i>et al.</i>
		WIPO/PCT	WO 89/00692	26 Jan 1989	Colcher <i>et al.</i>
		WIPO/PCT	WO 89/01783	9 May 1989	Bodmer <i>et al.</i>
		WIPO/PCT	WO 90/04410	3 May 1990	Gourlie <i>et al.</i>
		WIPO/PCT	WO 91/00295	10 Jan 1991	Hellstrom <i>et al.</i>
		WIPO/PCT	WO 93/12231	24 June 1993	Johnson <i>et al.</i>
		WIPO/PCT	WO 96/13594	9 May 1996	Benhar <i>et al.</i>
		WIPO/PCT	WO 97/26010	24 July 1997	Church <i>et al.</i>
		WIPO/PCT	WO 98/18809	7 May 1998	Finer <i>et al.</i>
		WIPO/PCT	WO 99/43816	9 Feb 1999	Armour <i>et al.</i>
		WIPO/PCT	WO 00/26394	11 May 2000	Kashmiri <i>et al.</i>
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS			

EXAMINER SIGNATURE:	/Parithosh K Tungaturthi/	DATE CONSIDERED:	12/20/2007
---------------------	---------------------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/519580

EXPRESS MAIL LABEL NO. EV352377100US
Date of Deposit: December 27, 2004
D Rec'd PCT/PTO 27 DEC 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66176-05
		Application Number	Not yet assigned
		Filed	Herewith
		First Named Inventor	Kashmiri
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
/PKT/		ABERGEL <i>et al.</i> , "Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab'," <i>Proteins: Structure, Function, and Genetics</i> 17:438-443, 1993.	
		COLCHER <i>et al.</i> , "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies," <i>Cancer Research</i> 48:4597-4603, August 15, 1988.	
		DE PASCALIS <i>et al.</i> , "Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody," <i>J. Immunol.</i> 169:3076-3084, 2002	
		DE PASCALIS <i>et al.</i> , "In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants," <i>Clin. Can. Res.</i> 9:5521-5531, 2003	
		DIVGI <i>et al.</i> , "Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen," <i>Nucl. Med. Biol.</i> 21(1):9-15, 1994.	
		GONZALES <i>et al.</i> , "Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues," <i>Mol. Immunol.</i> 40:337-349, 2003	
		HAKIMI <i>et al.</i> , "Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys," <i>J. Immunol.</i> 147:1352-1359, 1991	
		HAND <i>et al.</i> , "Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma," <i>Cancer Supplement</i> 73(3):1105-1113, February 1, 1994	
		IWAHASHI <i>et al.</i> , "CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity," <i>Mol. Immunol.</i> 36:1079-1091:1999	
		JOHNSON <i>et al.</i> , "Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3," <i>Cancer Research</i> 46:850-857, February 1986	
		JONES <i>et al.</i> , "Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse," <i>Nature</i> 321:522-525, May 29, 1986	
		KASHMIRI <i>et al.</i> , "Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49," <i>Hybridoma</i> 14(5):461-473, 1995	
		KASHMIRI <i>et al.</i> , "Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49," <i>Crit. Rev. Oncol. Hematol.</i> 38:3-16, 2001	
		KASHMIRI <i>et al.</i> , Chapter 21 in <i>Methods in Molecular Biology</i> , Vol. 248: <i>Antibody Engineering: Methods and Protocols</i> , p. 361-376; Lo (ed.), Humana Press, Inc., Tolowa, NJ, 2003	

EXAMINER SIGNATURE:	/Parithosh K Tungaturthi/	DATE CONSIDERED:	12/20/2007
---------------------	---------------------------	------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/519580

EXPRESS MAIL LABEL NO. EV352377100US

Date of Deposit: December 27, 2004

Docket Rec'd PC/PD 27 DEC 2004

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	4239-66176-05
Application Number	Not yet assigned
Filed	Herewith
First Named Inventor	Kashmiri
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

/PKT/	MULLIGAN <i>et al.</i> , "Phase I Study of Intravenous ¹⁷⁷ Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma," <i>Clinical Cancer Research</i> 1:1447-1454, December 1995
	MURARO <i>et al.</i> , "Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen," <i>Cancer Research</i> 48:4588-4596, August 15, 1988
	PADLAN, "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties," <i>Molecular Immunology</i> 28(4/5):489-498, 1991
	PADLAN, "Anatomy of the antibody molecule," <i>Mol. Immunol.</i> 31:169-217, 1994.
	PADLAN <i>et al.</i> , "Identification of Specificity-determining Residues in Antibodies," <i>The FASEB Journal</i> 9:133-139, January 1995
	PAUL, <i>Fundamental Immunology</i> , Raven Press, NY, Ch. 8, p. 242, 1993
	REICHMAN <i>et al.</i> , "Reshaping human antibodies for therapy," <i>Nature (London)</i> 332:323-327, 1988.
	RIXON <i>et al.</i> , "Preferential Use of a H Chain V Region in Antitumor-associated Glycoprotein-72 Monoclonal Antibodies," <i>The Journal of Immunology</i> 151(11):6559-6568, December 1, 1993
	RUDIKOFF <i>et al.</i> , "Single amino acid substitution altering antigen-binding specificity," <i>Proc Natl Acad Sci U S A</i> . March; 79(6): 1979-1983, 1982
	SALDANHA <i>et al.</i> , "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <i>Mol. Immunol.</i> 36:709-719, 1999
	SCHIER <i>et al.</i> , "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," <i>J. Mol. Biol.</i> 263:551-567, 1996
	SHA <i>et al.</i> , "A heavy-chain grafted antibody that recognizes the tumor-associated TAG72 antigen," <i>Cancer Biother.</i> 9(4):341-349, 1994
	SHARKEY <i>et al.</i> , "Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies," <i>Cancer Res.</i> 55:5935s-5945s, 1995
	SLAVIN-CHIORINI <i>et al.</i> , "Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins," <i>Cancer Res.</i> 55(23 Suppl.):5957s-5967s, 1995.

EXAMINER SIGNATURE:	/Parithosh K Tungaturthi/	DATE CONSIDERED:	12/20/2007
---------------------	---------------------------	------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/519580

EXPRESS MAIL LABEL NO. EV352377100US
Date of Deposit: December 27, 2004

27 DEC 2004

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	4239-66176-05
Application Number	Not yet assigned
Filed	Herewith
First Named Inventor	Kashmiri
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

/PKT/	SLAVIN-CHIORINI <i>et al.</i> , "A CDR-grafted (humanized) domain-deleted antitumor antibody," <i>Cancer Biother. Radiopharm.</i> 12:305-316, 1997
	TAMURA <i>et al.</i> , "Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only," <i>J. Immunol.</i> 164:1432-1441, 2000
	WU <i>et al.</i> , "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues," <i>J. Mol. Biol.</i> 294:151-162, 1999
	XIANG <i>et al.</i> , "The tyrosine residue at position 97 in the VH CDR3 region of a mouse/human chimeric anti-colorectal carcinoma antibody contributes hydrogen bonding to the TAG72 antigen," <i>Cancer Biother.</i> 8:253-262, 1993
	XIANG <i>et al.</i> , "Complementarity determining region residues aspartic acid at H55, serine at H95 and tyrosines at H97 and L96 play important roles in the B72.3 antibody-TAG-72 antigen interaction," <i>Protein Eng.</i> 9:539-543, 1996
	XIANG <i>et al.</i> , "Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding," <i>Protein Eng.</i> 12:417-421, 1999.

EXAMINER SIGNATURE:	/Parithosh K Tungaturthi/	DATE CONSIDERED:	12/20/2007
---------------------	---------------------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <p>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>MAY 05 2006</p>		Attorney Docket Number	4239-66176-05
		Application Number	10/519,580
		Filing Date	July 11, 2005
		First Named Inventor	Kashmiri
		Art Unit	1643
		Examiner Name	Parithosh K. Tungaturthi
Initials*	Cite No. (optional)	OTHER DOCUMENTS	
/PKT/		ADAMS and SCHIER, "Generating improved single-chain Fv molecules for tumor targeting," <i>Journal of Immunological Methods</i> , 231(1-2):249-260, 1999.	
/PKT/		DE PASCALIS <i>et al.</i> , "In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants," <i>Clinical Cancer Research</i> , 9(15):5521-5531, 2003.	
/PKT/		OSBOURN <i>et al.</i> , "Generation of a panel of related human scFv antibodies with high affinities for human CEA," <i>Immunotechnology</i> , 2(3):181-196, 1996.	
/PKT/		Supplementary Partial European Search Report issued on February 27, 2006, for European Patent Application No. EP03762161.2.	

EXAMINER SIGNATURE:	/Parithosh K Tungaturthi/	DATE CONSIDERED:	12/20/2007
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			